Atezolizumab With FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer in the First-line Setting

At the 2023 American Society of Clinical Oncology (ASCO) annual meeting, Carlotta Antoniotti, MD, PhD, University of Pisa, shares updated data and overall survival results from the AtezoTRIBE study. This study found a benefit to progression-free survival with the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer patients in the first-line setting.